NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.

[1]  P. Jänne,et al.  U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors , 2020, Clinical Cancer Research.

[2]  A. Markham.  Tepotinib: First Approval , 2020, Drugs.

[3]  M. Ladanyi,et al.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.

[4]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[5]  M. Ladanyi,et al.  ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Kengo Watanabe,et al.  The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models , 2019, Nature Communications.

[7]  S. Keam,et al.  Entrectinib: First Global Approval , 2019, Drugs.

[8]  A. Zehir,et al.  Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy , 2019, The Journal of molecular diagnostics : JMD.

[9]  F. Penault-Llorca,et al.  Testing algorithm for identification of patients with TRK fusion cancer , 2019, Journal of Clinical Pathology.

[10]  Jessica L. Davis,et al.  TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Sellers,et al.  Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation , 2019, Clinical Cancer Research.

[12]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[13]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[14]  J. Swensen,et al.  Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.

[15]  A. Drilon,et al.  Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.

[16]  D. Hong,et al.  Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins , 2018, Clinical Cancer Research.

[17]  C. Fletcher,et al.  Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.

[18]  Jessica L. Davis,et al.  Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors , 2018, The American journal of surgical pathology.

[19]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[20]  M. Ladanyi,et al.  Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.

[21]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[22]  A. Drilon,et al.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance , 2017, Nature Reviews Clinical Oncology.

[23]  F. Meric-Bernstam,et al.  Targeting TRK family proteins in cancer , 2017, Pharmacology & therapeutics.

[24]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[25]  A. Isacchi,et al.  Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. , 2016, Journal of medicinal chemistry.

[26]  A. Sartore-Bianchi,et al.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.

[27]  E. Giovannetti,et al.  Entrectinib: a potent new TRK, ROS1, and ALK inhibitor , 2015, Expert opinion on investigational drugs.

[28]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[29]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[30]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[31]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[32]  T. Vaněček,et al.  Mammary Analogue Secretory Carcinoma of Salivary Glands With High-grade Transformation: Report of 3 Cases With the ETV6-NTRK3 Gene Fusion and Analysis of TP53, &bgr;-Catenin, EGFR, and CCND1 Genes , 2014, The American journal of surgical pathology.

[33]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[34]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[35]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[36]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[37]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[38]  I. Screpanti,et al.  TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. , 2004, Cancer cell.

[39]  Combating Acquired TRK Inhibitor Resistance. , 2019, Cancer discovery.

[40]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[41]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[42]  C. Gomez-Fernandez,et al.  Searching for mammary analog secretory carcinoma of salivary gland among its mimics , 2014, Modern Pathology.

[43]  S. Skaper.  The neurotrophin family of neurotrophic factors: an overview. , 2012, Methods in molecular biology.

[44]  E. Huang,et al.  Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.